Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors

Cancer Gene Therapy

Volumn 22, Issue 1, 2015, Pages 9-16

  Orciani, M ^a   Davis, S ^b   Appolloni, G ^a   Lazzarini, R ^a   Mattioli Belmonte, M ^a   Ricciuti, R A ^c   Boscaro, M ^d   Di Primio, R ^a   Arnaldi, G ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c OSPEDALI RIUNITI   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CORTICOTROPIN; FOLLITROPIN; GROWTH HORMONE; HYPOPHYSIS HORMONE; KRUPPEL LIKE FACTOR 4; LUTEINIZING HORMONE; OCTAMER TRANSCRIPTION FACTOR 4; PROLACTIN; THYROTROPIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR PIT 1; TRANSCRIPTION FACTOR PITX2; TRANSCRIPTION FACTOR PROP1; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MEMBRANE ANTIGEN; MESSENGER RNA;

ADIPOGENESIS; ADULT; AGED; ARTICLE; BONE DEVELOPMENT; CELL ISOLATION; CELLS BY BODY ANATOMY; CHONDROGENESIS; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GROWTH HORMONE RELEASE; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MESENCHYMAL STEM CELL; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; CANCER STEM CELL; CELL DIFFERENTIATION; CELL MOTION; CELL TRANSFORMATION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHENOTYPE;

ADULT; AGED; ANTIGENS, SURFACE; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; NEOPLASTIC STEM CELLS; PHENOTYPE; PITUITARY NEOPLASMS; RNA, MESSENGER;

EID: 84921885456     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.63     Document Type: Article

References (36)

1. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101: 613-619.
2. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol 2011; 7: 257-266.
3. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
4. Wang JC. Good cells gone bad: the cellular origins of cancer. Trends Mol Med 2010; 16: 145-151.
5. Wang ML, Chiou SH, Wu CW. Targeting cancer stem cells: emerging role of Nanog transcription factor. Onco Targets Ther 2013; 6: 1207-1220.
6. Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M et al. Isolation of tumour stem-like cells from benign tumours. Br J Cancer 2009; 101: 303-311.
7. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
8. Irollo E, Pirozzi G. CD133: to be or not to be, is this the real question? Am J Transl Res 2013; 5: 563-581.
9. Orciani M, Gorbi S, Benedetti M, Di Benedetto G, Mattioli-Belmonte M, Regoli F et al. Oxidative stress defense in human-skin-derived mesenchymal stem cells versus human keratinocytes: Different mechanisms of protection and cell selection. Free Radic Biol Med 2010; 49: 830-838.
10. Orciani M, Campanati A, Salvolini E, Lucarini G, Di Benedetto G, Offidani A et al. The mesenchymal stem cell pro file in psoriasis. Br J Dermatol 2011; 165 : 585-592.
11. Orciani M, Di Primio R. Skin-derived mesenchymal stem cells: isolation, culture, and characterization. Methods Mol Biol 2013; 989: 275-283.
12. Salvolini E, Lucarini G, Zizzi A, Orciani M, Di Benedetto G, Di Primio R. Human skin-derived mesenchymal stem cells as a source of VEGF and nitric oxide. Arch Dermatol Res 2010; 302: 367-374.
13. Halfon S, Abramov N, Grinblat B, Ginis I. Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev 2011; 20: 53-66.
14. Kim MJ, Shin KS, Jeon JH, Lee DR, Shim SH, Kim JK et al. Human chorionic-plate-derived mesenchymal stem cells and Wharton's jelly-derived mesenchymal stem cells: a comparative analysis of their potential as placenta-derived stem cells. Cell Tissue Res 2011; 346: 53-64.
15. Orciani M, Emanuelli M, Martino C, Pugnaloni A, Tranquilli AL, Di Primio R. Potential role of culture mediums for successful isolation and neuronal differentiation of amniotic fluid stem cells. Int J Immunopathol Pharmacol 2008; 21: 595-602.
16. Orciani M, Morabito C, Emanuelli M, Guarnieri S, Sartini D, Giannubilo SR et al. Neurogenic potential of mesenchymal-like stem cells from human amniotic fluid: the influence of extracellular growth factors. J Biol Regul Homeost Agents 2011; 25: 115-130.
17. Salvolini E, Orciani M, Lucarini G, Vignini A, Tranquilli AL, Di Primio R. VEGF and nitric oxide synthase immunoexpression in Down's syndrome amniotic fluid stem cells. Eur J Clin Invest 2011; 41: 23-29.
18. Lazzarini R, Olivieri F, Ferretti C, Mattioli-Belmonte M, Di Primio R, Orciani M. mRNAs and miRNAs profiling of mesenchymal stem cells derived from amniotic fluid and skin: the double face of the coin. Cell Tissue Res 2014; 355 : 121-130.
19. Castinetti F, Davis SW, Brue T, Camper SA. Pituitary stem cell update and potential implications for treating hypopituitarism. Endocr Rev 2010; 32: 453-471.
20. de Moraes DC, Vaisman M, Conceic¸ão FL, Ortiga-Carvalho TM. Pituitary development: a complex, temporal regulated process dependent on specific transcriptional factors. J Endocrinol 2012; 215: 239-245.
21. Ward RD, Raetzman LT, Suh H, Stone BM, Nasonkin IO, Camper SA. Role of PROP1 in pituitary gland growth. Mol Endocrinol 2005; 19: 698-710.
22. Zhu X, Gleiberman AS, Rosenfeld MG. Molecular physiology of pituitary development: signaling and transcriptional networks. Physiol Rev 2007; 87: 933-963.
23. Bao B, Ahmad A, Li Y, Azmi AS, Ali S, Banerjee S, Kong D et al. Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opin Ther Targets 2012; 16: 1041-1054.
24. Jamal M, Rath BH, Tsang PS, Camphausen K, Tofilon PJ. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia 2012; 14: 150-158.
25. Yunoue S, Arita K, Kawano H, Uchida H, Tokimura H, Hirano H. Identification of CD133+ cells in pituitary adenomas. Neuroendocrinology 2011; 94 : 302-312.
26. Nassiri F, Cusimano M, Zuccato JA, Mohammed S, Rotondo F, Horvath E et al. Pituitary stem cells: candidates and implications. Pituitary 2013; 16: 413-418.
27. Lloyd RV, Hardin H, Montemayor-Garcia C, Rotondo F, Syro LV, Horvath E et al. Stem cells and cancer stem-like cells in endocrine tissues. Endocr Pathol 2013; 24: 1-10.
28. De Coppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007; 25: 100-106.
29. Couly G, Coltey P, Eichmann A, Le Douarin NM. The angiogenic potentials of the cephalic mesoderm and the origin of brain and head blood vessels. Mech Dev 1995; 53: 97-112.
30. Etchevers HC, Vincent C, Le Douarin NM, Couly GF. The cephalic neural crest provides pericytes and smooth muscle cells to all blood vessels of the face and forebrain. Development 2001; 128: 1059-1068.
31. Yamanishi E, Takahashi M, Saga Y, Osumi N. Penetration and differentiation of cephalic neural crest-derived cells in the developing mouse telencephalon. Dev Growth Differ 2012; 54: 785-800.
32. Phinney DG. Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem 2012; 113: 2806-2812.
33. Le H, Zeng F, Xu L, Liu X, Huang Y. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer. Mol Med Rep 2013; 8: 1511-1518.
34. Ren F, Sheng WQ, Du X. CD133: a cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol 2013; 19: 2603-2611.
35. Yang K, Chen XZ, Zhang B, Yang C, Chen HN, Chen ZX et al. Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis. Int J Biol Markers 2011; 26: 173-180.
36. Östman A. Cancer-associated fibroblasts: recent developments and emerging challenges. Semin Cancer Biol 2014; 25: 1-2.